| Project/Area Number |
15K10636
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Akita University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MIURA MAASTOMO 秋田大学, 医学部, 教授 (30265194)
SAITO MITSURU 秋田大学, 医学部, 講師 (80400505)
KOMATSUDA ATSUSHI 秋田大学, 医学部, 准教授 (70272044)
NIIOKA TAKENORI 秋田大学, 医学部, 講師 (20722276)
OKUYAMA SHIN 秋田大学, 医学部, 准教授 (40543286)
FUJIYAMA NOBUHIRO 秋田大学, 医学部, 助教 (90603275)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | タクロリムス / 遺伝子多型 / 薬物動態 / 薬理遺伝学 / 線維増生 / 画像解析 / 個別投与量設計 / 拒絶反応 / 繊維増生 / CYP3A5 / ドナー特異抗体 / 腎線維化 / 血中濃度 / 腎移植 / 免疫抑制薬 |
|---|
| Outline of Final Research Achievements |
We investigated the impact of CYP3A5 pharmacogenetic differences on the development of interstitial fibrosis (IF) from 0 hours to 1 year post-transplantation in 96 living kidney recipients under the same target trough regimen of tacrolimus. The relationships among CYP3A5 polymorphisms, long-term graft function, and death-censored graft survival were also examined. The mean increase in the ratio of percent IF from 0 hours to 1 year was 1.38±0.74-fold. Trough levels of tacrolimus were lower in carriers with the CYP3A5*1 allele than in those with the CTP3A5*3/*3 genotype throughout the 1 year post-transplantation period. However, CYP3A5 genetic differences were not associated with the development of IF, any clinical events, or the long-term function and survival of grafts. The clinical impact of CYP3A5 pharmacogenetic differences may be small under the current lower target trough levels with suitable therapeutic drug monitoring in a lower immunological risk population.
|
